STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

VKTX VIKING THERAPEUTICS StockScouter® Report

5

StockScouter® Score

VIKING THERAPEUTICS, a mid cap company in the healthcare sector, is expected to slightly outperform the market over the next six months with average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The multi-period measure of relative price change and consistency is above average. Positive/Neutral
  • One or more less experienced analysts has modestly increased quarterly earnings estimates for VKTX. Positive/Neutral

 

Concerns

  • The most recent quarterly earnings report was significantly lower than analysts’ consensus forecast. Negative
  • Earnings growth in the past year has decelerated rapidly compared to earnings growth in the past three years. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be neutral, stocks will be , and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 60% done.
Progress: 80% done.
Low
High

Core Model Grades

D
C
N/A
B

Previous Ratings

2
5
2

 

Disclaimer: StockScouter is a registered trademark of Verus Analytics, Inc. All Verus Analytics materials available through this site are published solely for informational purposes and are not to be construed as advice or a recommendation to specific individuals. Individuals should take into account their personal financial circumstances in acting on any rankings or stock selections provided by Verus Analytics. Verus Analytics makes no representations that the techniques used in its rankings or selections will result in or guarantee profits in trading. Trading involves risk, including possible loss of principal and other losses, and past performance is no indication of future results. Verus Analytics may have previously distributed the information in its reports and analyses in different forms. The owners and executives of Verus Analytics and its partners 1) may own individual stocks rated by the StockScouter system, 2) have no influence on the ratings, and 3) do not act on ratings changes before they are made publicly available.